Specialty Area
Spotlight
Topics
Institute for Value-Based Medicine
About AJMC
Podcasts
CE
Subscribe
- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Unraveling GLP-1 Agonists and Cardiovascular Protection
A panelist discusses how glucagon-like peptide-1 receptor (GLP-1) agonists' cardioprotective effects likely stem from multiple physiological mechanisms, including reduced inflammation, improved glucose metabolism, enhanced endothelial function, and potential antiatherosclerotic properties that collectively lower the risk of cardiac events.
Video content above is prompted by the following:
- What insights can be gathered from the study “Propensity Score-Matched Analysis of GLP-1 Agonists' Impact on Clinical Cardiovascular Outcomes in Patients With Concurrent Heart Failure and Atrial Fibrillation,” and how does propensity score matching enhance the reliability of findings from this analysis of 51,446 patients with heart failure?
- What mechanisms might explain the reduced rates of cardiac arrest and acute myocardial infarction in the GLP-1 agonist group?
- How might these findings potentially change atrial fibrillation treatment approaches for patients with heart failure?
Related Content
In VERIFY, Rusfertide Spares Most Patients With PV a Phlebotomy for 32 Weeks, Improves QOL
June 3rd 2025Article
Adding rusfertide to standard of care more than doubled the share of patients with polycythemia vera (PV) who did not meet criteria for a phlebotomy, according to data from the VERIFY trial.
Read More
